Intellia Therapeutics, Inc. NASDAQ:NTLA

Intellia Therapeutics stock price today

$10.25
-1.72
-14.37%
Financial Health
0
1
2
3
4
5
6
7
8
9

Intellia Therapeutics stock price monthly change

-53.59%
month

Intellia Therapeutics stock price quarterly change

-53.59%
quarter

Intellia Therapeutics stock price yearly change

-62.29%
year

Intellia Therapeutics key metrics

Market Cap
1.22B
Enterprise value
2.47B
P/E
-5.57
EV/Sales
47.48
EV/EBITDA
-5.40
Price/Sales
55.02
Price/Book
2.32
PEG ratio
0.08
EPS
-5.35
Revenue
52.60M
EBITDA
-512.35M
Income
-485.50M
Revenue Q/Q
129.53%
Revenue Y/Y
-1.62%
Profit margin
-909.78%
Oper. margin
-879.04%
Gross margin
0%
EBIT margin
-879.04%
EBITDA margin
-973.99%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Intellia Therapeutics stock price history

Intellia Therapeutics stock forecast

Intellia Therapeutics financial statements

Average Price Target
Last Year

$39

Potential upside: 280.48%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Profit margin
Jun 2023 13.59M -123.68M -909.82%
Sep 2023 11.99M -122.22M -1019.21%
Dec 2023 -1.91M -132.16M 6894.16%
Mar 2024 28.93M -107.43M -371.3%
Intellia Therapeutics, Inc. (NASDAQ:NTLA): Debt to assets
Jun 2023 1323240000 218.35M 16.5%
Sep 2023 1243349000 205.93M 16.56%
Dec 2023 1300977000 250.80M 19.28%
Mar 2024 1259589000 223.45M 17.74%
Intellia Therapeutics, Inc. (NASDAQ:NTLA): Cash Flow
Jun 2023 -90.32M -34.53M 2.51M
Sep 2023 -101.38M 79.5M 19.10M
Dec 2023 -93.05M 45.93M 106.48M
Mar 2024 -120.66M 5.90M 59.99M

Intellia Therapeutics alternative data

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Employee count
Sep 2023 598
Oct 2023 598
Nov 2023 598
Dec 2023 598
Jan 2024 598
Feb 2024 598
Mar 2024 526
Apr 2024 526
May 2024 526
Jun 2024 526
Jul 2024 526

Intellia Therapeutics other data

56.36% -43.64%
of NTLA is owned by hedge funds
43.38M -34.52M
shares is hold by hedge funds

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Insider trades (number of shares)
Period Buy Sel
Jun 2023 0 5000
Jul 2023 0 2492
Oct 2023 0 265
Jan 2024 0 50528
Mar 2024 0 2902
Transaction Date Insider Security Shares Price per share Total value Source
Sale
BASTA JAMES officer: EVP, General Counsel
Common Stock 2,297 $32.99 $75,778
Sale
CLARK ELIANA officer: EVP, Chief Technical O..
Common Stock 605 $32.99 $19,959
Sale
SEPP-LORENZINO LAURA officer: EVP, Chi.. Common Stock 1,608 $28.66 $46,085
Sale
SEPP-LORENZINO LAURA officer: EVP, Chi.. Common Stock 1,608 $28.66 $46,085
Sale
SEPP-LORENZINO LAURA officer: EVP, Chi.. Common Stock 667 $29.38 $19,596
Sale
SEPP-LORENZINO LAURA officer: EVP, Chi.. Common Stock 667 $29.38 $19,596
Sale
HICKS DEREK officer: EVP, Chief Business Of..
Common Stock 3,877 $29.46 $114,216
Sale
BASTA JAMES officer: EVP, General Counsel
Common Stock 3,805 $29.46 $112,095
Sale
CLARK ELIANA officer: EVP, Chief Technical O..
Common Stock 307 $30.12 $9,247
Sale
CLARK ELIANA officer: EVP, Chief Technical O..
Common Stock 4,301 $29.46 $126,707
Friday, 20 December 2024
zacks.com
Tuesday, 3 December 2024
globenewswire.com
Tuesday, 26 November 2024
zacks.com
Monday, 25 November 2024
globenewswire.com
Friday, 22 November 2024
fool.com
Monday, 18 November 2024
seekingalpha.com
Saturday, 16 November 2024
globenewswire.com
Monday, 11 November 2024
seekingalpha.com
marketbeat.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Wednesday, 6 November 2024
fool.com
Tuesday, 5 November 2024
globenewswire.com
Monday, 4 November 2024
fool.com
Thursday, 31 October 2024
globenewswire.com
Monday, 28 October 2024
fool.com
Friday, 25 October 2024
seekingalpha.com
Thursday, 24 October 2024
fool.com
seekingalpha.com
schaeffersresearch.com
benzinga.com
globenewswire.com
Thursday, 17 October 2024
zacks.com
fool.com
Thursday, 10 October 2024
globenewswire.com
Wednesday, 9 October 2024
fool.com
Tuesday, 8 October 2024
zacks.com
Monday, 7 October 2024
globenewswire.com
  • What's the price of Intellia Therapeutics stock today?

    One share of Intellia Therapeutics stock can currently be purchased for approximately $10.25.

  • When is Intellia Therapeutics's next earnings date?

    Unfortunately, Intellia Therapeutics's (NTLA) next earnings date is currently unknown.

  • Does Intellia Therapeutics pay dividends?

    No, Intellia Therapeutics does not pay dividends.

  • How much money does Intellia Therapeutics make?

    Intellia Therapeutics has a market capitalization of 1.22B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 30.4% to 36.28M US dollars.

  • What is Intellia Therapeutics's stock symbol?

    Intellia Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NTLA".

  • What is Intellia Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Intellia Therapeutics?

    Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Intellia Therapeutics's key executives?

    Intellia Therapeutics's management team includes the following people:

    • Dr. John M. Leonard Pres, Chief Executive Officer & Director(age: 68, pay: $912,790)
    • Dr. Laura Sepp-Lorenzino Executive Vice President & Chief Scientific Officer(age: 64, pay: $609,380)
    • Mr. Glenn G. Goddard Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $562,450)
  • How many employees does Intellia Therapeutics have?

    As Jul 2024, Intellia Therapeutics employs 526 workers.

  • When Intellia Therapeutics went public?

    Intellia Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 6 May 2016.

  • What is Intellia Therapeutics's official website?

    The official website for Intellia Therapeutics is intelliatx.com.

  • Where are Intellia Therapeutics's headquarters?

    Intellia Therapeutics is headquartered at 40 Erie Street, Cambridge, MA.

  • How can i contact Intellia Therapeutics?

    Intellia Therapeutics's mailing address is 40 Erie Street, Cambridge, MA and company can be reached via phone at 857 285 6200.

  • What is Intellia Therapeutics stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Intellia Therapeutics in the last 12 months, the avarage price target is $39. The average price target represents a 280.48% change from the last price of $10.25.

Intellia Therapeutics company profile:

Intellia Therapeutics, Inc.

intelliatx.com
Exchange:

NASDAQ

Full time employees:

526

Industry:

Biotechnology

Sector:

Healthcare

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

40 Erie Street
Cambridge, MA 02139

CIK: 0001652130
ISIN: US45826J1051
CUSIP: 45826J105